Atlantic Healthcare company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

atlantichc.com

Stage

Private Equity | Alive

Total Raised

$25.4M

Last Raised

$24M | 6 yrs ago

About Atlantic Healthcare

Atlantic Healthcare an international specialty pharmaceutical company. The Company focuses on the development and commercialisation of products that address niche unmet needs. These products are intended for patients under the management of physicians in the hospital and specialist care sector which is showing one of the highest growth rates in the pharmaceutical industry.

Atlantic Healthcare Headquarter Location

Atlantic House 12 Rose & Crown Walk

Essex, England, CB10 1JH,

United Kingdom

+44 1799 513391

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Atlantic Healthcare

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Atlantic Healthcare is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Latest Atlantic Healthcare News

Research reveals high levels of long-term tofacitinib treatment persistence in UC

Mar 9, 2022

Disclosures: Panaccione reports financial support from AI4GI, AbbVie, Amgen, Arena Pharmaceuticals, Atlantic Healthcare, BioBalance, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Coronado Biosciences, Cosmo Technologies, Eagle, Eisai Medical Research, Elan, Eli Lilly, EnGene, Ferring Pharmaceuticals, Genentech, Gilead Sciences, Given Imaging, GlaxoSmithKline, Innomar, Janssen, Lycera, Meda, Merck & Co., Merck Research Laboratories, Novo Nordisk, PDL Biopharma, Pfizer Inc., Prometheus Laboratories, Protagonist, Receptos, Robarts Clinical Trials, Sandoz, Sanofi Genzyme, Satisfai Health, Shire Pharmaceuticals, Sigmoid Pharma, Specialty Rx, Sublimity, Takeda and TherAdvance. Please see the study for all other authors’ relevant financial disclosures. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact customerservice@slackinc.com . Back to Healio Researchers observed high levels of tofacitinib persistence for the long-term treatment of patients with ulcerative colitis, according to a study published in Alimentary Pharmacology & Therapeutics. The efficacy and safety of tofacitinib have been widely demonstrated in phase 2 and 3 induction and maintenance studies, as well as a long-term, phase 3 extension study known as OCTAVE Open. To further examine tofacitinib survival and persistence in patients with UC, Remo Panaccione, MD, of the University of Calgary, and colleagues conducted a post-hoc analysis of the OCTAVE Open, studying patients dosed with 5 mg or 10 mg twice daily up to 7 years. Of 603 patients, 280 entered the study with a clinical response (164 in remission), 220 entered as delayed responders, 75 as retreatment responders and 35 as dose-escalation responders. According to results, the median tofacitinib persistence among all responders was 5.6 years with estimated 2-year and 5-year drug survival rates higher among responders in remission (76.8% and 56.9%) compared with responders not in remission (69.8% and 50%). Researchers noted comparable median persistence among patients who were delayed responders (4.5 years), retreatment responders (4 years) and dose-escalation responders (4.4 years). Two-year and 5-year drug persistence rates were 69.5% and 45.2% among patients with a delayed response, 70.7% and 40% among patients with a retreatment response and 74.3% and 32.8% among patients with a dose-escalation response. Further analysis revealed that participants younger than 40 years, those dosed with tofacitinib 10 mg at baseline and those with prior tumor necrosis factor inhibitor failure were at greater risk for discontinuation from treatment in OCTAVE Open. “High levels of tofacitinib treatment persistence were observed across the selected subpopulations of patients analyzed in the OCTAVE Open open-label, long-term extension study that followed patients for up to 7 years, with median time to discontinuation ranging from 4 to 5.6 years,” Panaccione and colleagues concluded. “These data further support the use of tofacitinib in the long-term management of UC. Further research should focus on factors to enhance persistence with tofacitinib treatment in patients with UC.” Read more about

  • Where is Atlantic Healthcare's headquarters?

    Atlantic Healthcare's headquarters is located at Atlantic House, Essex.

  • What is Atlantic Healthcare's latest funding round?

    Atlantic Healthcare's latest funding round is Private Equity.

  • How much did Atlantic Healthcare raise?

    Atlantic Healthcare raised a total of $25.4M.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.